Hims & Hers on Monday released fourth-quarter results that disappointed on gross margin and sparked concerns about the future ...

Hims & Hers (HIMS) stock took a steep dive, dropping more than 27%Tuesday morning — even after the millennial-focused ...

Investors are scrambling to adjust, after the telehealth specialist Hims & Hers said it would stop selling an alternative to ...

After the FDA removed semaglutide injection products from a shortage list, compounders like Hims have 60-90 days to stop ...

Hims & Hers said on Monday that it may no longer be able to sell compounded versions of the weight-loss drug made by Novo ...

Hims & Hers Health Inc. shares lost as much as a fifth of their value in after-market trading Monday after the company said ...

Hims & Hers Health shares plunged in extended trading Monday after the online healthcare provider reported falling margins as ...

Hims & Hers Health reported fourth-quarter results on Monday that beat analysts’ expectations, but the stock sank in extended ...

Hims & Hers stock tumbled after the company confirmed it would stop selling some compounded weight-loss drugs.

The U.S. Food and Drug Administration said on Friday there was no longer a shortage of Novo Nordisk’s popular weight-loss and ...

With Hims & Her's main source of growth set to be extinguished, Citi analysts said its full-year guidance appears ...